Daily Ards Research Analysis
A preclinical study demonstrates that an inhalable nanozyme can bind damaged DNA and suppress cGAS-STING signaling, reducing inflammation and tissue injury in acute lung injury, offering a mechanistically targeted strategy for ARDS. A Thai cohort identifies low BMI and alcohol excess as risk factors for ARDS in pulmonary melioidosis, while a Brazilian ICU cohort shows driving pressure–guided PEEP matches ARDSNet low PEEP recommendations in COVID-19 ARDS, with notable differences in obesity.
Summary
A preclinical study demonstrates that an inhalable nanozyme can bind damaged DNA and suppress cGAS-STING signaling, reducing inflammation and tissue injury in acute lung injury, offering a mechanistically targeted strategy for ARDS. A Thai cohort identifies low BMI and alcohol excess as risk factors for ARDS in pulmonary melioidosis, while a Brazilian ICU cohort shows driving pressure–guided PEEP matches ARDSNet low PEEP recommendations in COVID-19 ARDS, with notable differences in obesity.
Research Themes
- Innate immune signaling and nanotherapeutics in ALI/ARDS
- Risk factors and outcomes of ARDS in tropical infections
- Ventilator management (PEEP titration) strategies in COVID-19 ARDS
Selected Articles
1. Regulation of cGAS-STING pathway with inhalable nanozyme in acute lung injury.
This preclinical study shows that inhalable CoAl-LDH nanozyme scavenges ROS and, uniquely, binds damaged DNA to suppress cGAS-STING signaling, dampening inflammatory cascades in ALI. Co-loading with the cGAS-STING inhibitor C176 further reduces inflammation and tissue injury, suggesting a targeted nanotherapeutic strategy for ARDS.
Impact: It identifies a previously unrecognized mechanism—nanozyme binding to damaged DNA to block cGAS-STING—and demonstrates inhalable delivery as a translationally attractive modality for ARDS.
Clinical Implications: While preclinical, targeting cGAS-STING via inhalable nanozymes could complement lung-protective ventilation by directly attenuating innate immune overactivation in ARDS.
Key Findings
- CoAl-LDH (CAL) nanosheets exhibit strong ROS scavenging and mitigate ALI inflammation.
- CAL binds damaged DNA and inhibits cGAS-STING–mediated inflammatory signaling (first demonstration).
- Co-incorporation of cGAS-STING inhibitor C176 enhances anti-inflammatory effects and reduces lung tissue damage.
Methodological Strengths
- Integrated bulk transcriptomics with single-cell sequencing reanalysis to elucidate mechanism.
- Inhalation delivery platform with demonstrated biocompatibility and functional synergy with a pathway inhibitor.
Limitations
- Preclinical study without human subjects; translational safety and dosing remain untested.
- Sample size and long-term toxicity/clearance data are not specified in the abstract.
Future Directions: Conduct GLP toxicology, pharmacokinetics, and aerosol performance studies, followed by early-phase trials to assess safety and biomarker modulation (cGAS-STING) in ARDS.
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening conditions marked by severe inflammation, oxidative stress, and disruption of the alveolar-capillary barrier. The limited efficacy of current therapies highlights the urgent need for novel approaches targeting key pathological mechanisms. Excessive generation of reactive oxygen species (ROS) and resulting cascade of amplified inflammatory responses is a key factor in the progression of ALI/ARDS. Herein, we successfully regulated the immune homeostasis-mediated inflammatory response to alleviate ALI based on the inhalable CoAl-LDH (CAL) nanosheets with good biocompatibility and exciting ROS scavenging capabilities. Transcriptomic analysis combined with single-cell sequencing reanalysis revealed, for the first time, that CAL binds to damaged DNA and effectively inhibits the cGAS-STING pathway-mediated inflammatory response. Furthermore, incorporating the cGAS-STING pathway inhibitor C176 into CAL greatly enhanced this inhibition to reduce inflammation and mitigate the lung tissue damage. These results suggest that regulation of immune homeostasis with multifunctional nanosheets may be a promising paradigm for managing ALI/ARDS in clinical settings.
2. Exploring patient characteristics and respiratory impacts of pulmonary melioidosis: A 5-year experience from endemic region of Thailand.
In a 5-year retrospective cohort from an endemic Thai region, 63.9% of pulmonary melioidosis cases met the 2024 ARDS definition, with most being moderate-to-severe. Excessive alcohol use and low BMI (<20 kg/m2) were associated with ARDS, and overall mortality was high (55.6%) without a significant difference by ARDS status.
Impact: Identifies modifiable and measurable risk factors (alcohol excess, low BMI) for ARDS in a neglected tropical disease, using the updated 2024 global ARDS definition.
Clinical Implications: Clinicians in endemic areas should screen for and address alcohol use and malnutrition in suspected melioidosis; anticipate early respiratory failure and plan for ICU-level support.
Key Findings
- 63.9% of pulmonary melioidosis cases met the 2024 global ARDS definition; 78% were moderate-to-severe.
- Excessive alcohol use (p=0.013) and BMI <20 kg/m2 (OR 6.0; 95% CI 1.080–33.321; p=0.041) associated with ARDS; BMI <20 remained independently associated (OR 29.27; 95% CI 1.849–463.678; p=0.017).
- Overall mortality was 55.6%; mortality did not differ significantly between ARDS and non-ARDS groups (65.2% vs 38.5%; p=0.169).
Methodological Strengths
- Microbiologically confirmed diagnosis of pulmonary melioidosis.
- Use of the 2024 global ARDS definition and multivariable modeling with reported odds ratios and CIs.
Limitations
- Single-center retrospective design with small sample size (n=36), limiting generalizability.
- Potential residual confounding and lack of detailed treatment stratification.
Future Directions: Prospective multicenter studies in endemic regions to validate risk factors and evaluate targeted interventions (nutrition, alcohol cessation) on ARDS incidence and outcomes.
BACKGROUND AND OBJECTIVE: Pulmonary melioidosis, caused by Burkholderia pseudomallei, emerges as the most prevalent and highly fatal manifestation of melioidosis. Despite being a global health concern, pulmonary melioidosis remains insufficiently studied and reported. RESEARCH QUESTION: Whether patients with pulmonary melioidosis have any potential characteristics or specific risk factors that are associated with their respiratory outcome's trajectory. METHODS: A 5-year retrospective cohort study was conducted. Electronic medical records of patients admitted for Burkholderia pseudomallei pneumonia between January 1, 2019 and December 31, 2023, at Chaophraya Abhaibhubejhr hospital, Prachinburi, Thailand were reviewed. RESULTS: Of 1,486 adults admitted with bacterial pneumonia, 36 patients (2.4%) were diagnosed with microbiologically confirmed pulmonary melioidosis. Thirty of 36 patients (83.3%) developed acute respiratory failure requiring mechanical ventilation within 24 hours after admission. Twenty-three of 36 (63.9%) met the 2024 global definition of acute respiratory distress syndrome (ARDS) with 78% being moderate-to-severe ARDS. Pulmonary melioidosis with ARDS was associated with excessive alcohol consumption (p = 0.013) and body mass index (BMI) < 20 Kg/m2 (odds ratio of 6, 95%CI 1.080-33.321, p = 0.041) when compared to non-ARDS. BMI < 20 Kg/m2 was also associated with ARDS development, independent of age (odds ratio of 29.27 (95%CI 1.849 - 463.678, p = 0.017). The overall mortality rate of pulmonary melioidosis was 55.6%, with no differences between patients with ARDS and non-ARDS (65.2% vs 38.5%, respectively; p = 0.169). CONCLUSION: ARDS frequently emerges in patients with pulmonary melioidosis requiring invasive mechanical ventilation and intensive care support. Excessive alcohol consumption and a low BMI status were associated with the development of ARDS in these patients.
3. Comparison of PEEP tables based on oxygenation vs. driving pressure-guided PEEP titration in patients with severe acute respiratory syndrome due to COVID-19.
In 91 COVID-19 ARDS patients (141 titrations), driving pressure–guided PEEP closely matched ARDSNet low PEEP recommendations (p=0.83) but differed from LOVS and ALVEOLI tables. Obese patients (BMI >30 kg/m2) showed significant differences across all methods, highlighting the need for individualized PEEP strategies.
Impact: Provides real-world comparative data linking driving pressure–guided PEEP selection to established ARDSNet guidance, with actionable insights for obese CARDS patients.
Clinical Implications: Driving pressure–guided titration can align with ARDSNet low PEEP in many CARDS patients; in obesity, clinicians should anticipate divergence and tailor PEEP accordingly.
Key Findings
- Driving pressure–guided PEEP was similar to ARDSNet low PEEP table (p=0.83).
- ΔP-guided PEEP differed significantly from LOVS and ALVEOLI tables (p<0.001).
- In patients with BMI >30 kg/m2, PEEP values differed significantly across all evaluated methods (p<0.001).
Methodological Strengths
- Direct head-to-head comparison of ΔP-guided titration with multiple PEEP-FiO2 tables.
- Inclusion of a clinically relevant obese subgroup analysis.
Limitations
- Retrospective single-center design with modest sample size.
- Limited to COVID-19 ARDS; no assessment of clinical outcomes (e.g., mortality, ventilator-free days).
Future Directions: Prospective trials comparing ΔP-guided vs table-guided PEEP targeting hard outcomes and stratified by obesity and chest wall mechanics.
PURPOSE: To evaluate the positive end-expiratory pressure (PEEP) values with decremental PEEP titration based on driving pressure (ΔP) were different in comparison with PEEP-FiO2 tables in patients with Severe Acute Respiratory Syndrome due to COVID-19 (CARDS). METHODS: Retrospective cohort study at academic ICU in Brazil with adults with SARS due to COVID-19. The PEEP titration obtained by Best-ΔP was compared with values from PEEP-FiO2 tables. RESULTS: A total of 91 patients were included (141 titrations), with a median PaO2/FiO2 of 133 (97-170). The PEEP titration by ΔP was similar to the ARDSnet table (p = 0.83) and different from the LOVs and ALVEOLI tables (p < 0.001). The subgroup of patients with body mass index (BMI) > 30 kg/m2 was different (n = 73, p < 0.001) in all FiO2-tables and best ΔP . CONCLUSIONS: The PEEP by titration based on ΔP was similar to the ARDSnet low PEEP table, both being different from the other tables. In obese patients, the PEEP found by titration was significantly different in all methods evaluated in this study.